東阿阿膠(000423.SZ)半年度淨利潤降77.62%至1.93億元
格隆匯8月21日丨東阿阿膠(000423.SZ)發佈2019年半年度報告,實現營業收入18.90億元,同比下降36.69%;歸屬於上市公司股東的淨利潤1.93億元,同比下降77.62%;歸屬於上市公司股東的扣除非經常性損益的淨利潤1.44億元,同比下降81.55%;基本每股收益0.3537元。
公司主要產品:阿膠與人蔘、鹿茸並稱“滋補三寶”,是傳承近3000年的滋補類名貴中藥材。(1)阿膠被最早的醫藥經典《神農本草經》列為滋補上品,《本草綱目》稱其為補血聖藥,目前阿膠已成為OTC規模最大單品,列滋補養生第一品牌。(2)複方阿膠漿,源於明代經典名方“兩儀膏”,中藥獨家品種,氣血雙補,39年品質保障,在氣血保養市場上遙遙領先。(3)阿膠糕,優選道地原材料,產品包裝採用中國風設計,更適合高端女性和有禮品需求的人羣,通過食補,自內而外煥發美麗真顏。(4)“真顏”品牌系列產品,實踐“內外兼修”健康理念,結合阿膠的養顏功能,瞄準女性美容市場。目前已有真顏小分子阿膠、阿膠紅參飲等產品,戰略儲備產品40餘種。
全產業鏈優勢:從上游原料基地建設,到下游OTC終端、商超、醫院、自建連鎖等營銷終端掌控,形成了全產業鏈掌控的模式優勢。在山東、內蒙古、遼寧等地建立了毛驢藥材標準養殖示範基地,在多個國家建立了採購網絡,實現控制涵養並舉,國內國際並重,確保公司可持續發展。與百強連鎖形成穩固的戰略合作,直供及重點連鎖終端銷量逐年穩步增長,網絡優勢明顯。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.